A Multicenter Assessment of ALD403 in Frequent Episodic Migraine

Inclusion Criteria:

- Diagnosis of migraine at ≤ 50 years of age (ICHD-II, 2004 Section 1)

- History of migraine ≥ 12 months with

- ≤ 14 headache days of which at least 4 have to be migraine days (migraine days
count as headache days) in each 28 day period in the 3 months prior to screening

- During the 28 days following the screening visit, the subject experiences ≤ 14
headache days of which at least 4 have to be migraine days (migraine days count
as headache days) as recorded in the eDiary

- No use of any botulinum toxin for migraine or for any other medical/cosmetic reasons
requiring injections in the head, face, or neck 4 months prior to screening and during
the 28 day period prior to randomization

- Headache eDiary was completed on at least 25 of the 28 days prior to randomization

Exclusion Criteria:

- Confounding pain syndromes, e.g. fibromyalgia, complex regional pain syndrome or any
pain syndrome that requires regular analgesia

- Psychiatric conditions that are uncontrolled and untreated, including conditions that
are not controlled for a minimum of 6 months prior to screening

- History or diagnosis of complicated migraine (ICHD- II, 2004 Section 1), chronic
tension-type headache, hypnic headache, cluster headache, hemicrania continua, new
daily persistent headache, migraine with brainstem aura, sporadic and familial
hemiplegic migraine

- Unable to differentiate migraine from other headaches

- Have any clinically significant concurrent medical condition

- Receipt of any monoclonal antibody treatment within 6 months of screening (within or
outside a clinical trial)

- Previously dosed with ALD403 or any monoclonal antibody targeting the CGRP pathway